Cargando…

Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models

Background: To investigate the prognostic value of circulating plasma cells (CPC) and establish novel nomograms to predict individual progression-free survival (PFS) as well as overall survival (OS) of patients with newly diagnosed multiple myeloma (NDMM). Methods: One hundred ninetyone NDMM patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Qianwen, Cai, Li, Zhang, Yuyang, Chen, Lei, Hu, Yu, Sun, Chunyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973368/ https://www.ncbi.nlm.nih.gov/pubmed/33747963 http://dx.doi.org/10.3389/fonc.2021.639528

Ejemplares similares

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients
por: Yan, Ge, et al.
Publicado: (2022)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients
por: You, Hongying, et al.
Publicado: (2022)

Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model
por: Yuan, Shuai, et al.
Publicado: (2023)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities
por: Jia, Shuangshuang, et al.
Publicado: (2022)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

A Nomogram Predicts Individual Prognosis in Patients With Newly Diagnosed Glioblastoma by Integrating the Extent of Resection of Non-Enhancing Tumors
por: Zhang, Zhe, et al.
Publicado: (2020)

The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen
por: Pang, Yanbin, et al.
Publicado: (2020)

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
por: Jian, Yuan, et al.
Publicado: (2022)

Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017)

High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics
por: Xia, Yuan, et al.
Publicado: (2023)

Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting
por: Bonello, Francesca, et al.
Publicado: (2022)

Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma
por: Dosani, T, et al.
Publicado: (2017)

Frequency and Prognosis of Pulmonary Metastases in Newly Diagnosed Gastric Cancer
por: Sun, Zepang, et al.
Publicado: (2019)

Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
por: Mian, Owais, et al.
Publicado: (2023)

A nomogram model for predicting distant metastasis of newly diagnosed colorectal cancer based on clinical features
por: He, Jiang-Hua, et al.
Publicado: (2023)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma
por: Zhang, Limei, et al.
Publicado: (2022)

Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis
por: Tan, Xiangyu, et al.
Publicado: (2021)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells
por: Papadhimitriou, Stefanos I., et al.
Publicado: (2022)

Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients
por: van Hest, Naomi, et al.
Publicado: (2023)

Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Limei, et al.
Publicado: (2023)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Circulating Glycan Monosaccharide Composite-Based Biomarker Diagnoses Colorectal Cancer at Early Stages and Predicts Prognosis
por: Li, Haoran, et al.
Publicado: (2022)

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
por: Zhai, Yujia, et al.
Publicado: (2021)

HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients
por: Garcia de Veas Silva, Jose Luis, et al.
Publicado: (2021)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer
por: Jin, Nana, et al.
Publicado: (2023)

Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma
por: Guan, Tao, et al.
Publicado: (2022)

Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma
por: Luo, Tiancheng, et al.
Publicado: (2020)

PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model
por: Lee, Byung-Hyun, et al.
Publicado: (2020)

Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations
por: Xiang, Yunhui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iq886rjgba60uari1mnvjqn68r